Alcohol: The Most Widely Used Drug in America, Explained
Legal, ubiquitous, underestimated. 105,400 alcohol-induced deaths in 2022 and a medication most clinicians still don't prescribe.
Body — 8 lenses: [Science: GABA-A positive allosteric modulator, NMDA antagonist, multiple neurotransmitter effects. Biology: dose-dependent CNS depression; acute risks (respiratory depression, injury, aspiration); chronic (hepatic, cardiovascular, cancer risk across 7 cancers per 2025 Surgeon General report, wernicke-korsakoff). Psychology: withdrawal can be fatal (seizures, DTs); craving neurobiology. Policy: age 21, OSHA workplace, ABC licensing, dram shop. Trends: 105,400 alcohol-induced deaths in 2022 — 30% pandemic-era surge. Social: sober-curious movement, NA beer boom, cultural normalization + medical reframing. Treatment: FDA-approved meds (naltrexone, acamprosate, disulfiram) — underused; only ~10% of AUD gets treatment. Motivational interviewing + CBT + 12-step. Harm reduction: managed drinking, eating+hydration, avoiding mixing with benzos/opioids, medically-managed withdrawal when needed.]
Sources Cited
- 01.A
- 02.A
Filed Under
sciencebiologypsychologypolicytrendssocial-culturaltreatmentharm-reductionPeer-Reviewed Research
Keep up with the reporting.
One email each morning with the stories that put days like this in context.
Continue reading
More from this section
Psilocybin Lowered Inflammation Markers in Parkinson's Patients. Don't Let Anyone Tell You What That Proves.
A JAMA Psychiatry study reports lower inflammation markers in people with Parkinson's disease after psilocybin. It was small and had no control group. What it can and cannot tell clinicians.
Science & MedicineDoubling the THC Doesn't Double the High. So Why Is Everyone Selling It That Way?
A meta-analysis of 41 THC experiments finds that doubling the dose from 5 to 10 mg raised the self-reported high by about 15 percent and left anxiety unchanged. What it means for people who use, and for providers.
Science & MedicineTwo Postdocs Are Telling the DEA That Schedule I Is Not a Place to Park Uncertainty
Students for Sensible Drug Policy, two early-career scientists and MindState Design Labs asked the DEA for a hearing on placing five tryptamines in Schedule I. What the proposal covers, what it doesn't, and who it could hit first.